KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Ann Hematol 104(1) 515-525

PMID39227450
PMCIDPMC11868237
DOI10.1007/s00277-024-05958-8
发表日期2024-09-03
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

The superiority and tolerability of daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus bortezomib/melphalan/prednisone (VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) was previously described in the global phase 3 ALCYONE study. The primary analysis of the phase 3 OCTANS study further demonstrated the superiority and tolerability of D-VMP (n = 144) versus VMP (n = 71) in transplant-ineligible Asian patients with NDMM. The current analysis describes the final efficacy and safety outcomes for D-VMP versus VMP in OCTANS, with a follow-up of > 3 years. D-VMP demonstrated a benefit versus VMP with regard to the rate of very good partial response or better (80.1% vs. 47.3%), median progression-free survival (38.7 vs. 19.2 months), median time to next treatment (46.8 vs. 20.6 months), rate of complete response or better (46.6% vs. 18.9%), median duration of response (41.3 vs. 18.5 months), achievement of minimal residual disease (MRD) negativity (40.4% vs. 10.8%), and sustained MRD negativity for ≥ 12 months (24.7% vs. 1.4%) and ≥ 18 months (15.1% vs. 1.4%). Median progression-free survival was longer among patients who achieved MRD negativity and sustained MRD negativity. The progression-free survival benefit observed with D-VMP was preserved across most clinically relevant subgroups, including patients with high-risk cytogenetics. No new safety concerns were identified with extended follow-up. This final analysis of OCTANS continues to demonstrate a clinical benefit for D-VMP versus VMP in transplant-ineligible Asian patients with NDMM, consistent with the global ALCYONE study, and supports the use of daratumumab combinations in this population. Trial registration: ClinicalTrials.gov Identifier NCT03217812 submitted July 13, 2017.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 3

Fig. 3 PFS in the ITT population PFS, progression-free survival; ITT, intent-to-treat; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; HR, hazard ratio; CI, confidence interval

PFS_in_the_ITT_population

PFS

Fig. 3 · Panel PFS_in_the_ITT_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel PFS_in_the_ITT_population 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
KM Figure1 个面板

Fig. 5

Fig. 5 OS in the ITT population. OS, overall survival; ITT, intent-to-treat; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; HR, hazard ratio; CI, confidence interval

OS_in_ITT_population

OS

Fig. 5 · Panel OS_in_ITT_population

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel OS_in_ITT_population 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient disposition D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone * Reason captured was “patient refused further study treatment”
非 KM Figure
Fig. 2Fig. 2 Depth of response with D-VMP and VMP in the ITT population shown as ( a ) best confirmed response and ( b ) MRD negativity (10 –5 ). D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; ITT, intent-to-treat; MRD, minimal residual disease; sCR, stringent complete response; CR, complete response; VGPR, very good partial response; PR, partial response; ORR, overall response rate
非 KM Figure
Fig. 4Fig. 4 Cytogenetic subgroup analysis of PFS in the ITT population PFS, progression-free survival; ITT, intent-to-treat; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; HR, hazard ratio; CI, confidence interval; ISS, International Staging System; NE, not estimable; HRCA, high-risk cytogenetic abnormality. *Renal insufficiency defined as baseline creatinine clearance ≤ 60 mL/min. † Standard cytogenetic risk defined as none of the following HRCAs: t(4;14), t(14;16), and del(17p). ‡ High cytogenetic risk defined as ≥ 1 of the following HRCAs: t(4;14), t(14;16), and/or del(17p). § Revised standard cytogenetic risk defined as none of the following HRCAs: t(4;14), t(14;16), del(17p), t(14;20), gain(1q21), and amp(1q21). ¶ Revised high cytogenetic risk defined as ≥ 1 of the following HRCAs: t(4;14), t(14;16), del(17p), t(14;20), gain(1q21), and/or amp(1q21). # Gain(1q21) defined as 3 copies of chromosome 1q21, with or without other HRCAs. ǁ Amp(1q21) defined as ≥ 4 copies of chromosome 1q21, with or without other HRCAs. ** Gain(1q21) or amp(1q21) defined as ≥ 3 copies of chromosome 1q21, with or without other HRCAs. †† 1 HRCA defined as only 1 of the following HRCAs: t(4;14), t(14;16), del(17p), t(14;20), gain(1q21), or amp(1q21). ‡‡ ≥2 HRCAs defined as ≥ 2 of the following HRCAs: t(4;14), t(14;16), del(17p), t(14;20), gain(1q21), and/or amp(1q21). §§ Isolated gain(1q21) defined as 3 copies of chromosome 1q21 without any other HRCAs. ¶¶ Isolated amp(1q21) defined as ≥ 4 copies of chromosome 1q21 without any other HRCAs. ## Isolated gain(1q21) or amp(1q21) defined as ≥ 3 copies of chromosome 1q21 without any other HRCAs. ǁǁ Gain(1q21) or amp(1q21) plus ≥ 1 HRCA defined as ≥ 3 copies of chromosome 1q21 plus ≥ 1 of the following HRCAs: t(4;14), t(14;16), del(17p), and/or t(14;20)
非 KM Figure